Current Report Filing (8-k)
January 06 2023 - 4:31PM
Edgar (US Regulatory)
0001739174
false
0001739174
2023-01-05
2023-01-05
0001739174
PHGE:UnitsEachConsistingOfOneShareOfCommonStockAndOneWarrantEntitlingHolderToReceiveOneHalfShareOfCommonStockMember
2023-01-05
2023-01-05
0001739174
PHGE:CommonStock0.0001ParValueMember
2023-01-05
2023-01-05
0001739174
PHGE:WarrantsEachExercisableForOnehalfOfShareOfCommonStockAtExercisePriceOf11.50PerShareMember
2023-01-05
2023-01-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 6, 2023 (January 5, 2023)
|
BiomX Inc. |
|
|
(Exact Name of Registrant as Specified in its Charter) |
|
Delaware |
|
001-38762 |
|
82-3364020 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
22 Einstein St., Floor 4
Ness Ziona, Israel |
|
7414003 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (972) 72-394-2377
|
n/a |
|
|
(Former name or former address, if changed since last report) |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Units, each consisting of one share of Common Stock and one Warrant entitling the holder to receive one half share of Common Stock
|
|
PHGE.U |
|
NYSE American |
Common Stock, $0.0001 par value
|
|
PHGE |
|
NYSE American |
Warrants, each exercisable for one-half of a share of Common Stock, at an exercise price of $11.50 per share
|
|
PHGE.WS |
|
NYSE American |
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements
of Certain Officers.
On January 5, 2023, Jonas Grossman and Dr. Gbola Amusa
each resigned from the Board of Directors (the “Board”) of BiomX Inc. (the “Company”), for personal reasons, effective
immediately. Mr. Grossman and Dr. Amusa did not advise the Company of any disagreement with the Company on any matter relating to its
operations, policies or practices. The Company is actively seeking new candidates to fill the vacancies on the Board.
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOMX INC. |
|
|
|
January 6, 2023 |
By: |
/s/ Jonathan Solomon |
|
|
Name: Jonathan Solomon |
|
|
Title: Chief Executive Officer |
BiomX (AMEX:PHGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
BiomX (AMEX:PHGE)
Historical Stock Chart
From Sep 2023 to Sep 2024